Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2026 | January 05, 2026 |
| Nuveen Corporate Income 2023 Target Term FundJHAA · Entity 126455 | Portfolio Manager | February 26, 2019 | April 04, 2019 |
| Nuveen Corporate Income November 2021 Target Term FundJHB · Entity 137527 | Portfolio Manager | March 26, 2019 | April 04, 2019 |
| Nuveen Global High Income FundJGH · Entity 992 | Portfolio Manager | March 26, 2019 | April 04, 2019 |
| Nuveen High Income 2020 Target Term FundJHY · Entity 150910 | Portfolio Manager | March 26, 2019 | April 04, 2019 |
| Nuveen High Income December 2019 Target Term FundJHD · Entity 150914 | Portfolio Manager | March 26, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 101,009 |
Reported balance
After 2026-01-01 transaction · row 1
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 27,322 · Balance 101,009 F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.
Nuveen Corporate Income 2023 Target Term Fund
Report date February 26, 2019 · Filed April 04, 2019
This filing explicitly reported no securities owned.
Nuveen Corporate Income November 2021 Target Term Fund
Report date March 26, 2019 · Filed April 04, 2019
This filing explicitly reported no securities owned.
Nuveen Global High Income Fund
Report date March 26, 2019 · Filed April 04, 2019
This filing explicitly reported no securities owned.
Nuveen High Income 2020 Target Term Fund
Report date March 26, 2019 · Filed April 04, 2019
This filing explicitly reported no securities owned.
Nuveen High Income December 2019 Target Term Fund
Report date March 26, 2019 · Filed April 04, 2019
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 21:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001772558-26-000002 · form4-01052026_040115.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,009 F1 · shares: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000426 · form4-01032025_040103.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,687 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:54 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000913 · tm241755-8_4seq1.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,304 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001099 · tm231728-5_4seq1.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,572 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 20:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053584 · tm2213913-5_4seq1.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,572 F1 · shares: One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 21:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048828 · tm219139d5_4.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,582 F1 · shares: One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 20:07 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033114 · tm2011481-5_form4.xml · nonDerivative · entry 1 Lorenz Kevin · CIK 0001772558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,582 F1 · shares: One-third of the shares will vest on each of January 1, 2021, 2022 and 2023, subject to continued service. F2 · balance_after: Includes 34,582 shares owned by Mr. Lorenz prior to his appointment to the Company's board in August 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.